Pfizer signs licence agreement with Chai for AI drug discovery

Pfizer and Chai Discovery have signed a licence deal enabling the former to incorporate Chai’s AI platform into its drug discovery operations. According to the agreement, Pfizer will become one of the first pharmaceutical companies to access Chai’s newly revealed Chai-3 model. Chai’s platforms streamline early drug discovery by designing biomolecules from scratch, targeting complex processes, and shortening cycles. Credit: Gorodenkoff / Shutterstock.com. Pfizer and Chai Discovery have agreed on a licensing deal enabling the former to incorporate Chai’s AI platform into its drug discovery operations. This partnership provides the biopharmaceutical company with early access to the Chai-3 model alongside…

Source: Pharmaceutical Technology